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Abstract: Non-typhoidal serovars of Salmonella enterica (NTS) are a leading cause of food-borne
disease in animals and humans worldwide. Like other zoonotic bacteria, NTS have the
potential to act as reservoirs and vehicles for the transmission of antimicrobial drug resistance
in different settings. Of particular concern is the resistance to critical “last resort” antimicrobials,
such as carbapenems. In contrast to other Enterobacteriaceae (e.g., Klebsiella pneumoniae,
Escherichia coli, and Enterobacter, which are major nosocomial pathogens affecting debilitated and
immunocompromised patients), carbapenem resistance is still very rare in NTS. Nevertheless, it has
already been detected in isolates recovered from humans, companion animals, livestock, wild animals,
and food. Five carbapenemases with major clinical importance—namely KPC (Klebsiella pneumoniae
carbapenemase) (class A), IMP (imipenemase), NDM (New Delhi metallo-β-lactamase), VIM (Verona
integron-encoded metallo-β-lactamase) (class B), and OXA-48 (oxacillinase, class D)—have been
reported in NTS. Carbapenem resistance due to the production of extended spectrum- or AmpC
β-lactamases combined with porin loss has also been detected in NTS. Horizontal gene transfer of
carbapenemase-encoding genes (which are frequently located on self-transferable plasmids), together
with co- and cross-selective adaptations, could have been involved in the development of carbapenem
resistance by NTS. Once acquired by a zoonotic bacterium, resistance can be transmitted from humans
to animals and from animals to humans through the food chain. Continuous surveillance of resistance
to these “last resort” antibiotics is required to establish possible links between reservoirs and to
limit the bidirectional transfer of the encoding genes between S. enterica and other commensal or
pathogenic bacteria.
Keywords: Salmonella enterica; multidrug resistance; carbapenems; carbapenemases; mobile genetic
elements; plasmids; porins
1. Introduction
Non-typhoidal serovars of Salmonella enterica (NTS) are among the most prevalent zoonotic
pathogens affecting animals and humans worldwide [1,2]. These bacteria are mainly transmitted
to humans through the ingestion of contaminated food of animal origin—particularly poultry, pork
and beef meat, milk, eggs, and derived products. However, many other foods—including fruits and
vegetables contaminated with animal or human feces—can also be involved [3].
In humans, NTS usually cause self-limiting gastroenteritis, characterized by diarrhea, abdominal
cramps, nausea, vomiting, and fever. With low frequency, the bacteria can spread beyond the
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intestine, giving rise to focal or invasive infections, which mostly occur in children, the elderly,
or immunocompromised patients [3]. The burden of foodborne NTS infections is very high, with global
estimations of 78.4 million cases, 28,693 deaths, and over 2 million DALYs (disability adjusted life
years) in 2010 [1].
Antimicrobial therapy is not usually required for intestinal infections affecting otherwise healthy
individuals, but it can be life-saving in the case of vulnerable patients and severe infections [4].
The emergence of resistance and multidrug resistance (MDR) can compromise the effectiveness
of the treatment [5]. Particularly worrisome is the increasing resistance or reduced susceptibility
to antimicrobials that are critically important for human medicine [6], including fluoroquinolones,
broad-spectrum cephalosporins (which are drugs of choice for the treatment of S. enterica invasive
infections [4]), and carbapenems [7–12]. The latter are among the most important antimicrobial
weapons available nowadays, since they are reserved as “last resort” antibiotics to combat severe
infections caused by MDR Gram-negative bacteria in hospitals [13,14].
This review reports the current state of carbapenem resistance in NTS. Although carbapenems are
not first-choice drugs for the treatment of Salmonella infections, the emergence of such resistance in
zoonotic pathogens poses a pressing threat to public health, as they may be transferred to humans
through the food chain. In humans, apart from causing disease, NTS may act as vehicles for
the transmission of resistance-encoding genes to other pathogenic bacteria and to bacteria of the
endogenous microbiota.
2. Carbapenem Resistance in Non-Typhoidal Serovars of S. enterica
In Gram-negative bacteria, resistance mechanisms to carbapenems include carbapenemase
production, as well as the production of extended-spectrum β-lactamases (ESBLs) or AmpC
β-lactamases together with the loss of specific outer membrane porins [15]. Although resistance
to carbapenems is still very rare in NTS, both mechanisms have already been reported.
2.1. Carbapenemase-Producing Non-Typhoidal S. enterica from Humans
The majority of the acquired carbapenemases belong to three of the four known classes of
β-lactamases [16]: Ambler class A, Ambler class B (zinc-dependent metallo-β-lactamases; MBLs),
and Ambler class D (oxacillinases; OXAs) [13,14]. Carbapenemases can hydrolyze the β-lactam ring
of carbapenems with different efficiency depending on the class; the majority are not inhibited by
traditional β-lactamase inhibitors such as clavulanic acid or tazobactam, and most but not all confer
resistance to other β-lactams, including broad-spectrum cephalosporins [13,14].
The increasing spread of carbapenemase-encoding genes in nosocomial enteric
bacteria—particularly K. pneumoniae and E. coli—raised the possibility of their dissemination
to NTS. In fact, these genes are often located on mobile genetic elements such as integrons, transposons,
and plasmids, which can efficiently contribute to their spread [17–19], and bla genes encoding enzymes
belonging to five families of carbapenemases with high clinical relevance in Enterobacteriaceae—that
is, KPC (Klebsiella pneumoniae carbapenemase) (class A), IMP (imipenemase), NDM (New Delhi
metallo-β-lactamase), VIM (Verona integron-encoded metallo-β-lactamase) (class B), and OXA-48
(class D) [11,12] have been already detected in S. enterica (Table 1).
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Table 1. Carbapenemase-encoding genes and plasmid location in non-typhoidal serovars of
Salmonella enterica from humans, animals, and food.
Gene Serovar Plasmid Inc a Origin Country Reference
Humans
blaKPC-2 Cubana + ukn Feces USA [20]
Typhimurium nt na Blood Colombia [21]
blaIMP-4 Waycross + ukn Urine/Feces Australia [22]
blaNDM-1 Senftenberg + L/M Perirectal swab United States Tv (India) [23,24]
Westhampton b nt na Perirectal swab Reunion Island Tv (India) [25]
Stanley + A/C Feces China [26,27]
Senftenberg + X3 Feces United Kingdom [28]
Senftenberg + A/C Feces India [29]
Agona nt na Feces Pakistan [30]
blaNDM-5 1,4,[5],12:i:- + FII Feces China [31]
blaVIM-2 Kentucky + W(UT) Urine/blood Morocco [32]
blaOXA-48 Saintpaul + L/M Blood/Feces France Tv (Egypt) [32]
Kentucky + ukn Feces France Tv (Egypt) [32]
Kentucky + L/M Perianal swab Switzerland Tv (Libya) [33]
Paratyphi B + L/M Feces United Kingdom Tv (Africa) [28]
Typhimurium + L/M Feces United Kingdom [28]
Animals and Food
blaVIM-1 Infantis + HI2 Swine and poultry farms Germany [34,35]
Infantis + HI2 Sick piglet Germany [36]
Infantis + HI2 Minced pork meat Germany [36]
blaNDM-1 Indiana + HI2 Chicken carcass China [37]
Corvallis + A/C Wild bird Germany [38]
blaIMP-4 Typhimurium + HI2 Cats Australia [39]
a Inc, incompatibility group; + present; ukn, unknown; nt, not tested; na, not applicable; UT, untypeable; b NDM-1
production was assumed based on the Indian provenance of the patient, but not demonstrated; Tv known
travel history.
The first carbapenemase gene ever reported in S. enterica was blaKPC-2, found in a clinical
isolate of S. Cubana in December 1998 [20]. The isolate was collected in the United States from
feces of a 4-year-old boy suffering from diarrhea, and exhibited either resistance or decreased
susceptibility to all β-lactam antibiotics tested, including β-lactam/β-lactamase inhibitor combinations,
oxymino-cephalosporins, monobactams, and carbapenems. The patient was chronically ill with
Wiskott–Aldrich syndrome, had been hospitalized several times before S. Cubana isolation, and had
received intravenous cephalosporins, but not carbapenems. blaKPC-2 was located on a conjugative
plasmid (designated pST4707), together with blaTEM-1 and several other antimicrobial resistance genes.
KPC-2 was later detected in S. Typhimurium recovered in 2013 from the blood of a 58-year-old
woman hospitalized in Colombia [21]. The isolate displayed clinical resistance to carbapenems,
broad-spectrum cephalosporins, aztreonam, and gentamicin, and intermediate susceptibility to
ciprofloxacin, but was susceptible to trimethoprim-sulfamethoxazole. KPC enzymes—particularly
KPC-2—are endemic in some areas of Latin America (including Colombia), the United States, Italy,
and Greece [13]. The S. Typhimurium isolate from Colombia could have gained blaKPC-2 from a
carbapenem-resistant E. coli previously found in a positive orotracheal secretion of the patient, who was
admitted to the hospital suffering from community-acquired pneumonia. However, the E. coli isolate
was not available for further characterization, and considering the endemicity of KPC producers in
Colombia, alternative donors of blaKPC-2 are possible [21].
The first-class B metallo-β-lactamase identified in NTS was IMP-4. This enzyme was reported in
S. Waycross recovered in 2007 in Australia from an 87-year old woman who had a urinary tract infection
followed by diarrhea [22]. The isolate, recovered from urine and fecal samples, was resistant or showed
intermediate susceptibility to most β-lactams, including imipenem, cefotaxime, and ceftriaxone,
and exhibited additional resistances to nalidixic acid, gentamicin, and amikacin. The blaIMP-4 gene
was carried by a class 1 integron together with the qacG, aacA4, and catB2 genes, which confer
resistance to quaternary ammonium compounds, aminoglycosides, and chloramphenicol, respectively.
Interestingly, the integron was located on an 80-kb conjugative plasmid that also harbored the
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PMQR (plasmid-mediated quinolone resistance) qnrB4 gene, which confers reduced susceptibility
to fluoroquinolones. Accordingly, this S. Waycross isolate carried emerging resistance determinants
which compromise the efficacy of the main families of antimicrobial agents used to combat severe
S. enterica infections, namely broad-spectrum β-lactams and fluoroquinolones [4].
Apart from IMP-4, NDM-1, and members of the VIM family are other class B carbapenemases
found in NTS. To date, the highest number of reports corresponds to NDM-1, which confers
resistance to all β-lactams except the monobactam aztreonam, and is produced by MDR and even
pandrug-resistant isolates [40]. NDM-1 was first identified in K. pneumoniae and E. coli isolates
recovered in 2008 from a patient hospitalized in Sweden after a previous stay in a New Delhi hospital,
hence the name [41]. Since then, NDM-1 producers have been detected worldwide, particularly in
patients linked to India or other countries of the Indian sub-continent [42].
Within this scenario, NDM-1 was initially reported in two NTS isolates during screenings for MDR
in patients transferred from India [23,25]. The first case relates to a 60-year old American man who
was transferred from India to a hospital in United States in 2011 due to an intracranial hemorrhage [23].
Soon after his arrival, a K. pneumoniae isolate was recovered from the endotracheal secretion of the
patient, who developed fever. The isolate was resistant to carbapenems, and the blaNDM-1 gene was
identified. Later on, the gene was also detected in an S. Senftenberg isolate from a perirectal swab of the
same patient from a surveillance culture. Although blaNDM-1-containing plasmids can be transferred
between enterobacterial species [42], the different restriction profiles and incompatibility groups of
the blaNDM-1 plasmids found in the carbapenem-resistant K. pneumoniae (IncA/C) and S. Senftenberg
(IncL/M) isolates argue against transfer of the plasmid from the former bacterium into the latter [23,24].
Colonization with carbapenem-resistant S. enterica was also reported in 2012, in a 73-year old
man transferred from India to a French hospital in Reunion Island [25]. The patient was originally
hospitalized in an Indian hospital with intracranial hemorrhage diagnosis, and was febrile with
purulent endotracheal secretions. ESBL-producing E. coli and ESBL-producing K. pneumoniae were
collected from urine and bronchoalveolar lavage fluid of the patient, respectively. After recovery and
transfer to Reunion Island, E. coli and K. pneumoniae with an ESBL phenotype were obtained from a
rectal swab of the patient, and an imipenem-resistant S. enterica isolate identified as S. Westhampton
was collected from urine and fecal samples. Considering the origin of the patient, NDM-1 production
was assumed, although the presence of blaNDM-1 was not confirmed.
The blaNDM-1 gene has also been detected in human clinical isolates of S. Stanley from China [26],
S. Senftenberg from the United Kingdom and India [28,29], and S. Agona from Pakistan [30].
The S. Stanley isolate from China was involved in a community-acquired case of diarrhea affecting
an 11-month old girl in 2012, who was successfully treated with azithromycin and latamoxef [26].
In S. Stanley, blaNDM-1 was located on a ca. 140-kb IncA/C conjugative plasmid. Whole sequence of the
plasmid (pHS36-NDM) identified two MDR islands [27]: (i) The ISEcp1-blaCMY transposition unit which
contains a CMY-6 β-lactamase gene (blaCMY-6) and a quaternary ammonium compound resistance
gene (sugE); and (ii) the intI1-ISCR27 accessory region, which carried a trimethoprim resistance gene
(dfrA12), two aminoglycoside resistance genes (aadA2 and rmtC), a truncated quaternary ammonium
compound resistance gene (qacE∆1), a sulfonamide resistance gene (sul1), the blaNDM-1 carbapenemase
gene, and the bleomycin resistance gene bleMBL. pHS36-NDM shared high homology with blaNDM-1
containing plasmids reported in Sweden, Italy, and Japan, although previous international travel
history was neither documented for the patient nor for her family. Moreover, pHS36-NDM belongs to
a different incompatibility group than other blaNDM-1 plasmids reported in China, and shows limited
homology in the surrounding structure of blaNDM-1 [27].
The S. Senftenberg isolate from the United Kingdom was found during a screening of carbapenem
resistance among cefotaxime-resistant NTS [28]. The isolate, obtained in 2008 from feces of an
outpatient with unknown travel history, was resistant to cefotaxime, ceftazidime, and ertapenem,
but susceptible to meropenem and imipenem. The blaNDM-1 gene was located on a ca. 53-kb IncX3
plasmid which showed 99.7% identity to an IncX3-type blaNDM-1 plasmid from a Raoultella planticola
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detected in China [43]. In both plasmids, ISAba125 (interrupted by IS5) and the bleomycin resistance
gene bleMBL were located upstream and downstream of blaNDM-1, respectively, and blaSHV-12 was the
only other co-resident resistance gene.
The S. Senftenberg from India was recovered in 2012 from the feces of a 5-year-old child with
diarrhea who attended the outpatient department of a hospital [29]. It was resistant to all antimicrobials
tested, with the single exception of tetracycline (according to CLSI guidelines), and carried the blaNDM−1
gene on a large conjugative plasmid of the IncA/C group, which also contained several other resistance
genes—including blaCMY-4.
Two more cases of infantile diarrhea (affecting a 9-month-old child and a 1-year-old child) caused
by NDM-1 producing S. enterica were reported in Pakistan [30]. The isolates, serotyped as S. Agona,
were only susceptible to azithromycin, fosfomycin, and colistin, and had identical pulsed-field gel
electrophoresis (PFGE) profiles, suggesting they originated from a common source. This S. Agona
strain and the S. Senftenberg isolate reported by Sarkar et al. [29] are the only NDM-1-producing NTS
detected thus far in the Indian sub-continent.
Recently, an isolate belonging to the monophasic variant of S. Typhimurium (antigenic formula
1,4,[5],12:i:- MLST type ST34) recovered from a fecal specimen from a child with acute diarrhea
in China proved to be positive for the blaNDM-5 gene [31]. NDM-5 differs from NDM-1 by
two amino acid substitutions (Val88Leu and Met154Leu) and confers high-level resistance to
carbapenems and broad-spectrum cephalosporins [44]. The blaNDM-5 gene of the monophasic
S. Typhimurium was located on an IncFII plasmid of 84.5 kb, together with blaTEM-1B and the
phosphotransferase mph(A) gene, which confers high-level resistance to azithromycin. Interestingly,
blaNDM-5 was flanked by sequences identical to those bordering the same gene in IncX3 plasmids
carried by other enterobacteria (E. coli, Klebsiella, and Enterobacter) from the same hospital
(IS3000-∆ISAba125-IS5-blaNDM-5-ble-trpF-dsbC-IS26). These results support the potential acquisition
of the IncX3 blaNDM-5 gene by the IncFII backbone. Detection of carbapenemase resistance in
S. Typhimurium 1,4,[5],12:i:- ST34 is a cause of concern, as this monophasic variant ranks among the
most common S. enterica serovars in many parts of the world [2,45–47].
The third class B metallo-β-lactamase detected in S. enterica was VIM-2, which is the most
common MBL reported worldwide [13]. This carbapenemase was identified in 2010 in Morocco in five
clinical isolates of S. Kentucky with decreased susceptibility to imipenem [32]. The isolates originated
from the blood (1) and urine (2) of hospitalized patients, and from stool samples (2) of outpatients.
They belonged to a highly epidemic and drug-resistant strain (S. Kentucky ST198; PFGE type X1) that
emerged in Egypt and spread through Africa and the Middle East from 2002 to 2008 [48]. The five
isolates harbored the blaVIM-2 gene (together with aacC7, aacC1, and aacA4 genes) within the In58
integron, carried on 30-kb IncW or untypeable plasmids. The VIM-2 producers were also resistant
to broad-spectrum cephalosporins and to ciprofloxacin, with the latter resistance due to the GyrA
(Ser83Phe, Asp87Gly) and ParC (Ser80Ile) substitutions characteristically associated with S. Kentucky
ST198-X1 from West Africa and Egypt. As pointed out by Le Hello et al. [32], such isolates had taken a
major step towards pandrug-resistance, imposing severe limitations to antimicrobial therapy.
In addition to class A and class B carbapenemases, the class D OXA-48 oxacillinase had also been
reported in human clinical isolates of NTS. The blaOXA-48 gene is usually detected in K. pneumoniae
and E. coli, but can also be found in other Enterobacteriaceae, such as Enterobacter [49–52]. In contrast to
other carbapenemases, OXA-48 is not active against broad-spectrum cephalosporins, and hydrolyzes
carbapenems only weakly [49]. This enzyme was first identified in Turkey in 2004, and since then it has
been detected in many other countries—mainly from the Middle East, North Africa, and Europe [13].
The blaOXA-48 gene is usually located on Tn1999-like transposons, carried by self-transferable plasmids
of about 60-kb belonging to the IncL/M incompatibility group, which are largely responsible for its
extensive dissemination between members of the Enterobacteriaceae [49]. In some countries, OXA-48
producers have actually become more frequent than isolates producing the classic KPC, NDM, and VIM
carbapenemases [53–55].
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In 2009, Le Hello et al. [32] detected two OXA-48-producing S. enterica isolates in a 69-year
old woman who returned to France from a holiday in Egypt, where OXA-48 is endemic. The first
isolate, taken from blood and stool cultures, was identified as S. Saintpaul, displayed intermediate
susceptibility to imipenem, and carried the blaOXA-48 gene on a conjugative IncL/M plasmid with an
estimated size of about 70-kb. The second isolate, recovered in 2011 from the feces of the same patient,
was grouped with the S. Kentucky ST198-X1 strain. It displayed resistance towards ciprofloxacin
attributed to GyrA (Ser83Phe, Asp87Gly) and ParC (Ser80Ile) substitutions, and harbored the mph(A)
gene conferring high-level resistance to azithromycin. This isolate also proved positive for blaOXA-48,
although it was susceptible to imipenem in vitro.
OXA-48-producing S. Kentucky ST198 was also collected in 2012 from perianal screening culture
of a patient transferred from Libya (another country endemic for OXA-48) to a rehabilitation clinic
in Switzerland [33]. The blaOXA-48 gene was carried by Tn1999.2 and located on a ca. 60-kb IncL/M
plasmid. The isolate also possessed the blaVEB-8, aac(6)-Ib, tet(A), sul1, and mph(A) resistance genes,
as well as substitutions in GyrA (Ser83Phe and Asp87Asn) and ParC (Ser80Ile). Accordingly, it was
resistant to multiple antimicrobial agents, including broad-spectrum cephalosporins, azithromycin,
and ciprofloxacin, and showed reduced susceptibility to imipenem.
Finally, single isolates of S. Paratyphi B phage type (PT) Dundee and S. Typhimurium PT193—both
positive for blaOXA-48—were recovered in 2013 from hospitalized patients with diarrhea in the United
Kingdom [28]. The first patient reported a history of travel to Africa, but the second did not recount
recent travels. The S. Paratyphi B and S. Typhimurium isolates showed intermediate susceptibility
to ertapenem and cefotaxime, and were susceptible to meropenem, imipenem, and ceftazidime.
The blaOXA-48 gene was located on a 62-kb IncL/M plasmid.
2.2. Carbapenemase-Producing Non-Typhoidal S. enterica from Animals and Food
The first carbapenemase-producing S. enterica recovered from livestock were three S. Infantis
isolates detected in different swine and poultry farms in Germany during 2011–2012 [34,35].
These isolates carried blaACC-1 and blaVIM-1 genes, conferring resistance to penicillins,
first-to-fourth-generation cephalosporins, and β-lactam/β-lactam inhibitors, as well as decreased
susceptibility to carbapenems. They had additional resistances to chloramphenicol, streptomycin,
sulfonamides, and trimethoprim, but were susceptible to colistin, fosfomycin, nitrofurantoin,
and tigecycline. blaACC-1 and blaVIM-1 co-localized on a 300-kb IncHI2 conjugative plasmid designated
pRH-R27, which was fully sequenced [56]. The blaVIM-1 gene was part of a class 1 integron (In110) that
also contained aacA4 and aadA1. The strA/B, catA1 genes together with genes conferring resistance to
heavy metals were carried by the same plasmid. Related IncHI2 VIM-1-plasmids were also found in
concomitant E. coli strains isolated from German farms [35,56,57]. Two additional isolates belonging to
the same VIM-1-producing S. Infantis clone were recently reported [36]. One of them was isolated in
2015 from minced pork meat produced in Germany, and the other isolate from a sick piglet in 2016 in
the same country. The MIC (minimum inhibitory concentration) values against meropenem of all the
VIM-1 producing S. Infantis isolates reported so far were close to the epidemiological cut-off values
of EUCAST (www.eucast.org)—a fact that could make their detection difficult. When the isolates
described in [34] were grown in media containing higher concentrations of carbapenems, the isolates
expressed clinical resistance to these antibiotics. The finding of similar isolates both from pigs and
meat derived thereof suggests the possible vertical transmission of these isolates through the food
chain [36].
Apart from the above-mentioned S. Infantis isolate from minced pork meat, the only other
carbapenem-resistant S. enterica detected thus far in food was an S. Indiana isolate cultured from a
slaughtered chicken carcass in China [37]. Whole genome sequencing of the isolate revealed the location
of the blaNDM-1 gene on a very large plasmid (pC629 of 210-kb), together with many other resistance
genes, leading to an extensively-drug-resistant phenotype, including blaCTX-M-65, the plasmid-mediated
quinolone resistance genes aac(6′)-Ib-cr, oqxA, oqxB, and oqxR, and the fosA and mph(A) genes responsible
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for resistance to fosfomycin and macrolides, respectively. Two virulence genes were also identified on
plasmid pC629. In Acinetobacter baumanii, these genes are required for a capsule-positive phenotype
important for bacterial protection against the host immune system [58]. S. enterica isolates carrying
VIM- and KPC-encoding genes were also found in retail chicken products in China, but none of them
exhibited resistance to the carbapenems tested (imipenem or meropenem) [59].
Finally, it is of note that the blaIMP-13 gene was present as an incomplete gene cassette in a class
1 integron found in MDR isolates of S. Typhimurium and S. Anatum obtained from food samples
in Colombia [60], and that several carbapenem-resistant serovars of S. enterica have been recovered
from vegetables in India (S. Teko, S. Weltevreden, and S. Saintpaul; [61]) and from buffalo calves and
beef in the same country (S. Paratyphi B variant Java, S. Saintpaul and S. Virchow) [62]. However,
the responsible genes were not identified, despite some inconsistences in the susceptibility data.
With regard to companion animals, a carbapenemase-producing S. Typhimurium, positive for
blaIMP-4, was recently recovered from a systemically ill (index) cat and three additional cats at an
animal shelter in Australia [39]. All isolates were identical and belonged to ST19. Genome sequencing
revealed the acquisition of a 339-kb IncHI2 plasmid (pIMP4-SEM1) that encoded resistance to nine
antimicrobial classes including carbapenems, and carried the blaIMP-4-qacG-aacA4-catB3 cassette array.
blaIMP-4 is considered endemic in Australia, and the integron containing this gene has been detected in
a variety of plasmids, comprising IncHI2, IncA/C, IncL/M, or IncI1 backbones [39].
In addition to livestock and domestic animals, wild animals can also act as reservoirs of
carbapenemase-producing bacteria [11,12]. In this respect, a S. Corvallis isolate (MLST type ST1541),
obtained from a black kite (Milvus migrans) in Germany showed carbapenem susceptibility values
consistent with the presence of a carbapenemase gene, and blaNDM-1 was indeed detected [38].
The isolate had a ca. 188-kb type 1 IncA/C2 conjugative plasmid. Full sequencing of the plasmid
(pRH-1238; referred as pRH-1738 in [38]) identified the blaNDM-1, blaCMY-16, fosA3, sul1, sul2, strA, strB,
aac(6′)-Ib, aadA5, aphA6, tet(A), mph(A), floR, dfrA7, and merA genes, which confer clinically relevant
resistance to most of the antimicrobial classes, including all β-lactams except aztreonam, fosfomycin,
aminoglycosides, co-trimoxazole, tetracyclines, and macrolides [63]. The S. Corvallis isolate also
carried the qnrS gene for plasmid-mediated quinolone resistance; however, it was susceptible to
tigecycline and nitrofurantoin [38]. The differences observed between pRH-1238 and other sequenced
NDM-1-IncA/C2 plasmids identified in bacteria from Western countries, as well as the presence of
the fosA3 gene that is still rare in Europe but frequent in China, suggest a possible Asiatic origin of
the NDM-1 producing S. Corvallis. The bacterium was probably transferred from Asia to Germany
through the M. migrans migratory route, supporting that new routes of the spread of MDR bacteria
from Eastern to Western countries are possible through migratory birds [63]. In a broiler chicken
infection study with S. Corvallis, the pRH-1238 plasmid was transferred to other Enterobacteriaceae
including E. coli and K. pneumoniae, demonstrating the high transfer capability of the plasmid in-vivo
and its broad-host range [64].
2.3. Other Mechanisms of Carbapenem Resistance in Non-Typhoidal S. enterica
Apart from carbapenemase production, carbapenem resistance can arise from the production of
ESBLs or AmpC β-lactamases combined with porin loss. This mechanism is common in E. coli and
K. pneumoniae [65,66], but has rarely been reported in S. enterica.
Interestingly, consistent with the high adaptability of bacteria to environmental stress, a clinical
S. Typhimurium strain developed carbapenem resistance during ertapenem treatment [67]. The isolate
was identified in a 77-year-old woman with nephritic syndrome and chronic renal insufficiency who
was admitted in 2010 to the emergency unit of a hospital in Taiwan with a urinary tract infection.
The original isolate was resistant to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole,
ceftriaxone, and ciprofloxacin, but susceptible to carbapenems, had a Tn6092-blaCMY-2 transposon
located on a self-transferable IncI1 plasmid, and showed OmpD (analogous to OmpF in E. coli)
deficiency. The patient was treated with ertapenem and developed diarrhea during therapy. Stool
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culture yielded S. Typhimurium with the same features as the original isolate, and this was also the case
for follow-up cultures of both urine and stool specimens. After recovery, the patient was discharged,
but had to be hospitalized again owing to a right leg crush injury. Subsequently, she had persistent
diarrhea and was treated again with ertapenem. The new S. Typhimurium isolate recovered from feces
developed OmpC deficiency through a single gene mutation leading to premature termination of the
protein, and became resistant to carbapenem. Similarly, in a single isolate of S. Wien obtained from a
neonate’s blood in Tunis, resistance to imipenem was attributed to CMY-4 production along with loss
of an immune-related OmpF porin [68].
It is finally of note that, contrary to expectation, in vitro experiments performed by Saw et al. [69]
indicated that inactivation or inhibition of the AcrAB-TolC efflux pump in carbapenemase-producing
Enterobacteriaceae—including S. Typhimurium—led to decreased susceptibility to carbapenems,
and that this was likely due to changes in porin expression (e.g., OmpF). Consequently, efflux
inhibitors may not potentiate carbapenem activity, but could rather increase the levels of resistance in
carbapenemase-producing organisms.
3. Discussion
Carbapenems are critical “last resort” antibiotics reserved for the treatment of serious infections
caused by MDR Gram-negative bacteria, particularly in patients with prolonged hospital stays [70].
Accordingly, the use of carbapenems mostly occurs in hospitals and the highest proportion of
carbapenem-resistant bacteria derives from this setting, where the selective pressure is strong.
In contrast to other Enterobacteriaceae (e.g., K. pneumoniae, E. coli, and Enterobacter spp.), the clinical
impact of S. enterica as a human nosocomial pathogen is rather limited, and so is the frequency
of carbapenem resistance. Nevertheless, carbapenemase production has already been detected in
a variety of serovars from human clinical samples, including S. Agona, S. Cubana, S. Kentucky,
S. Paratyphi B, S. Typhimurium and its monophasic 1,4,[5],12:i:- variant, S. Saintpaul, S. Senftenberg,
S. Stanley, S. Waycross, and S. Westhampton (Table 1). Some of these serovars are frequently involved
in human and animal infections. For instance, this is the case of S. Typhimurium, its monophasic
variant, S. Indiana, and S. Kentucky, which are also characterized by a high level of MDR—particularly
associated with the spread of successful clones. These three serovars ranked among the top ten
associated with human infections in the European Union [71].
Although the source of carbapenemase-encoding genes could not be traced in most cases, they are
likely to derive from other human bacteria. In agreement with this, the genes carried by S. enterica
mostly coincide with those endemic in hospitals of the country. For example, this is the case of KPC-2
(found in S. Cubana and S. Typhimurium in the United States and Colombia, respectively), NDM-1
(detected in different countries and serovars, particularly in patients living in or being transferred
from the Indian sub-continent), and OXA-48 (mainly detected in patients transferred to Europe from
North African countries). Interestingly, NDM-1-producing S. enterica were not only associated with
infections, but also with the colonization of persons who spent time in the Indian sub-continent.
These findings emphasize the need for active screenings after traveling to avoid further spread of
carbapenemase-producers imported from endemic regions [12].
Even though NTS have limited significance as human nosocomial pathogens, this is not the
case in veterinary hospitals, where infections caused by these bacteria are an ongoing problem
worldwide, particularly in equine patients [72]. In contrast to human medicine, carbapenems have
never been licensed for use in livestock animals in any country [73]. However, sporadic cases of
carbapenemase-producing NTS have already been reported not only in companion animals (which may
be treated with carbapenems with caution and only under exceptional circumstances), but also in
livestock, food, and wild animals (Table 1). Thus, reservoirs other than human nosocomial bacteria,
as well as new ways of transmission—including the food chain—are now possible. Moreover,
the high level of MDR among carbapenemase producers, and the frequent linkage of resistance genes
within discrete genetic elements, including self-transferable and mobilizable plasmids, could allow
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co-selection by antimicrobials other than carbapenems used in agriculture. In fact, multiple plasmid
backbones were demonstrated to be involved in the spread of carbapenem resistance genes in
Gram-negative bacteria [17–19], and several of them have already been detected in NTS (Table 1).
It has also been proposed that the widespread use of extended spectrum β-lactams such
as ceftiofur (third-generation cephalosporin) in nearly all food animal species worldwide could
exert a selective pressure not only for resistance to extended-spectrum cephalosporins, but also
for carbapenem resistance [74], since most carbapenemases confer resistance to extended spectrum
cephalosporins. Carbapenem-resistant bacteria, including E. coli, have been detected in pigs and
dairy cattle from farms with frequent use of ceftiofur [74,75]. The E. coli isolates from dairy cattle
carried blaCMY-2 and truncated ompF genes, but lacked a carbapenemase gene. In contrast, the pig
isolates harbored the metallo-β-lactamase gene blaIMP-27 on IncQ1 plasmids. Similar cross-selective
adaptations as well as horizontal gene transfer from E. coli and other enterobacteria could give rise to
carbapenem-resistant NTS.
In small animal medicine there is great concern regarding the common use of the two
third-generation cephalosporins cefovecin and cefpodoxime, which are marketed for administration
as a convenient single long-acting subcutaneous injection. Consequently, they are used preferentially
as first-choice drugs in veterinary medicine, even though drugs with a narrower spectrum of activity
such as amoxicillin and cephalexin would be effective. The use of third-generation cephalosporins
in this manner is inappropriate and detrimental, as they should be reserved for exceptional use only,
being like carbapenems in the category of critically important antimicrobials for human medicine
and having a high risk of spreading resistance [6]. Within the context of the One Health approach,
a prudent use of these antimicrobial agents, following the expert’s recommendations, will be critical to
control the spread of resistance [76].
In conclusion, horizontal gene transfer together with co- and cross-selection mechanisms can be
involved in the development of carbapenem resistance in NTS. Global epidemiological surveillance
of carbapenem resistance in these zoonotic pathogens is required to establish possible links between
reservoirs and to limit the bidirectional transfer of the encoding genes between S. enterica and other
bacteria. In the European Union, surveillance of carbapenem (meropenem, ertapenem, and imipenem)
resistance and presumptive carbapenenemase-producing Salmonella and E. coli from food animals and
food derived thereof in the different Member States is included in the Legislation [77].
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